iKena Oncology reports Q1 EPS (33c), consensus (41c)

Reports Q1 revenue $0, consensus $1.75M. As of March 31 the Company had cash, cash equivalents, and marketable securities of $157.3M, which the Company believes will be sufficient to fund operations into the second half of 2026. “We continue to execute thoughtfully and diligently on our clinical programs,” said Mark Manfredi, CEO of Ikena. “With the dedication of our hyper-focused team and strong balance sheet, we are well positioned to build value for our shareholders by pursuing the development of novel, targeted therapies for patients.”